CN118355030A - 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途 - Google Patents

抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途 Download PDF

Info

Publication number
CN118355030A
CN118355030A CN202280070414.4A CN202280070414A CN118355030A CN 118355030 A CN118355030 A CN 118355030A CN 202280070414 A CN202280070414 A CN 202280070414A CN 118355030 A CN118355030 A CN 118355030A
Authority
CN
China
Prior art keywords
seq
heavy chain
antibody
light chain
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280070414.4A
Other languages
English (en)
Chinese (zh)
Inventor
濮瀑
张松龄
靳英
M·P·麦格威廉姆斯
M-C·冯
M·L·邱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuowei Innovative Biotechnology Hong Kong Co ltd
Original Assignee
Tuowei Innovative Biotechnology Hong Kong Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuowei Innovative Biotechnology Hong Kong Co ltd filed Critical Tuowei Innovative Biotechnology Hong Kong Co ltd
Publication of CN118355030A publication Critical patent/CN118355030A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280070414.4A 2021-10-18 2022-10-17 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途 Pending CN118355030A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256705P 2021-10-18 2021-10-18
US63/256,705 2021-10-18
PCT/US2022/078192 WO2023069888A1 (en) 2021-10-18 2022-10-17 ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN118355030A true CN118355030A (zh) 2024-07-16

Family

ID=84267971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280070414.4A Pending CN118355030A (zh) 2021-10-18 2022-10-17 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途

Country Status (8)

Country Link
US (1) US20250230248A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419556A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538148A (cg-RX-API-DMAC7.html)
KR (1) KR20240099227A (cg-RX-API-DMAC7.html)
CN (1) CN118355030A (cg-RX-API-DMAC7.html)
AU (1) AU2022369278A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232216A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023069888A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454705A1 (en) * 2023-04-28 2024-10-30 Jost B. Jonas Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
EP4746970A1 (en) * 2023-09-12 2026-05-27 Jost B. Jonas Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells
IL328594A (en) * 2023-11-23 2026-07-01 Velavigo Bio Inc Binding molecule and antibody-drug conjugate and their uses
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
CN118085101A (zh) * 2024-03-01 2024-05-28 烟台蓝纳成生物技术有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2026145588A1 (en) * 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
GB0520872D0 (en) * 2005-10-14 2005-11-23 Hofmann Thomas F Onion flavour compounds and use
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN102361884A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN106046161B (zh) * 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
EA033463B1 (ru) 2014-11-27 2019-10-31 Panasonic Ip Man Co Ltd Блок стеклянных панелей
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
EP4592313A3 (en) * 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用

Also Published As

Publication number Publication date
KR20240099227A (ko) 2024-06-28
WO2023069888A1 (en) 2023-04-27
US20250230248A1 (en) 2025-07-17
AU2022369278A1 (en) 2024-05-02
JP2024538148A (ja) 2024-10-18
EP4419556A1 (en) 2024-08-28
CA3232216A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
KR102505383B1 (ko) Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
US20250230248A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
CN103703026B (zh) 单特异性和双特异性抗igf-1r和抗erbb3抗体
WO2022155263A2 (en) Chimeric molecules comprising il-12 agonist polypeptide
US20230052369A1 (en) Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
EP4421093A1 (en) Antigen-binding protein comprising two fc domains and use thereof
CN116615253A (zh) 与叶酸受体α结合的重链抗体
TW202216767A (zh) 與CD3及FolR1結合之抗體
CN117751144A (zh) 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途
JP2025508692A (ja) 免疫複合体及びその使用
US20240383990A1 (en) Hinge-modified bispecific antibodies
TW202442679A (zh) 抗-fgfr2b抗體及其用途
US20240262879A1 (en) IL-12 Fc FUSION PROTEINS
TW202509065A (zh) 經pd-1調節之il-2免疫結合物及其用途
JP2024532478A (ja) 高い熱安定性及び減弱したエフェクター機能を有するFcバリアント
CN117715940A (zh) 抗trem-1抗体
WO2025201242A1 (en) Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
CN121816368A (zh) 一种包含免疫缀合物的药物组合物及其用途
KR20240156564A (ko) 두 개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
KR20250133603A (ko) 항-tigit/항-pd-l1 이중특이적 항체 및 이의 용도
CN119213034A (zh) 双功能蛋白质及其制剂和用途
CN117136198A (zh) 激动性抗il-2r抗体及其使用方法
HK40084724A (en) Engineered anti-her2 bispecific proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination